Selected article for: "health care and urgent need"
Author: Lima-Morales, René; Méndez-Hernández, Pablo; Flores, Yvonne N.; Osorno-Romero, Patricia; Cuecuecha-Rugerio, Elizabeth; Nava-Zamora, Adrián; Hernández-Galdamez, Diego Rolando; Romo-Dueñas, Daniela Karola; Salmerón, Jorge
Title: Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico
  • Cord-id: 4gof1yl8
  • Document date: 2021_2_10
    • ID: 4gof1yl8
    Snippet: Objective There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. The aim of this study was to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast and Acetylsalicylic Acid (“TNR4” therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Design and Methods A comparative effectiveness study was performed am
    Document: Objective There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. The aim of this study was to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast and Acetylsalicylic Acid (“TNR4” therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Design and Methods A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18 to 80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment. Results Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. Likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group. Conclusions TNR4 therapy improved recovery and prevented risk of hospitalization and death among ambulatory COVID-19 cases.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abdominal pain and acute respiratory illness: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and admission status: 1, 2
    • abdominal pain and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and logistic regression model: 1, 2
    • abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
    • abdominal pain and low prevalence: 1, 2, 3, 4
    • abdominal pain and lung imaging: 1, 2, 3, 4, 5, 6
    • abdominal pain and lung parenchyma: 1
    • ace inhibitor and acute phase: 1
    • ace inhibitor and admission status: 1
    • ace inhibitor and logistic regression: 1, 2, 3, 4, 5, 6, 7
    • ace inhibitor and logistic regression model: 1, 2
    • ace inhibitor and lung imaging: 1
    • acetylsalicylic acid and acute phase: 1
    • acetylsalicylic acid and logistic regression: 1, 2
    • acute phase and additional benefit: 1
    • acute phase and admission status: 1, 2, 3, 4
    • acute phase and local transmission: 1, 2